These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 3103805

  • 21. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
    Olmos G, Gabilondo AM, Miralles A, Escriba PV, García-Sevilla JA.
    Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S, Justinova Z, Lee SH, Stefanski R, Goldberg SR, Tanda G.
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [Abstract] [Full Text] [Related]

  • 24. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
    Fowler CJ, Mantle TJ, Tipton KF.
    Biochem Pharmacol; 1982 Nov 15; 31(22):3555-61. PubMed ID: 6817759
    [Abstract] [Full Text] [Related]

  • 25. Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies?
    Lewinsohn R, Glover V, Sandler M.
    Biochem Pharmacol; 1980 Mar 01; 29(5):777-81. PubMed ID: 20227955
    [Abstract] [Full Text] [Related]

  • 26. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K.
    J Pharmacol Exp Ther; 1987 Jan 01; 240(1):251-8. PubMed ID: 3100771
    [Abstract] [Full Text] [Related]

  • 27. Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
    Baud P, Arbilla S, Cantrill RC, Scatton B, Langer SZ.
    J Pharmacol Exp Ther; 1985 Oct 01; 235(1):220-9. PubMed ID: 3930699
    [Abstract] [Full Text] [Related]

  • 28. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
    Severina IS, Klimova GI, Nersisian AA.
    Biokhimiia; 1981 Nov 01; 46(11):2043-55. PubMed ID: 6797482
    [Abstract] [Full Text] [Related]

  • 29. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
    Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL.
    Psychopharmacology (Berl); 1987 Nov 01; 91(3):293-6. PubMed ID: 2436247
    [Abstract] [Full Text] [Related]

  • 30. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
    Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW.
    J Neurochem; 1990 Sep 01; 55(3):981-8. PubMed ID: 2117053
    [Abstract] [Full Text] [Related]

  • 31. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
    Fozard JR, Zreika M, Robin M, Palfreyman MG.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov 01; 331(2-3):186-93. PubMed ID: 3937059
    [Abstract] [Full Text] [Related]

  • 32. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
    Schoepp DD, Azzaro AJ.
    J Neurochem; 1981 Jun 01; 36(6):2025-31. PubMed ID: 6787175
    [Abstract] [Full Text] [Related]

  • 33. Evidence for a single catalytic binding site on human brain type B monoamine oxidase.
    Roth JA.
    J Neurochem; 1976 Nov 01; 27(5):1107-12. PubMed ID: 12170596
    [Abstract] [Full Text] [Related]

  • 34. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.
    Braestrup C, Andersen H, Randrup A.
    Eur J Pharmacol; 1975 Nov 01; 34(1):181-7. PubMed ID: 1241962
    [Abstract] [Full Text] [Related]

  • 35. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl.
    Robinson JB.
    Biochem Pharmacol; 1985 Dec 01; 34(23):4105-8. PubMed ID: 3933519
    [Abstract] [Full Text] [Related]

  • 36. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].
    Deverina IS.
    Biokhimiia; 1980 Oct 01; 45(10):1897-908. PubMed ID: 6786369
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
    Barbelivien A, Nyman L, Haapalinna A, Sirviö J.
    Pharmacol Toxicol; 2001 Jun 01; 88(6):304-12. PubMed ID: 11453370
    [Abstract] [Full Text] [Related]

  • 38. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
    Tekes K, Magyar K.
    Neurobiology (Bp); 2000 Jun 01; 8(3-4):257-64. PubMed ID: 11225517
    [Abstract] [Full Text] [Related]

  • 39. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I.
    Neuropsychopharmacol Hung; 2008 Mar 01; 10(1):15-22. PubMed ID: 18771016
    [Abstract] [Full Text] [Related]

  • 40. The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.
    Rényi L.
    Br J Pharmacol; 1986 Aug 01; 88(4):827-35. PubMed ID: 3091132
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.